RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation. In today’s announcement, RoosterBio announced that it has entered into a Cooperative Research and Development Agreement (CRADA) that will enable “collaborative development of innovative stem cell-based therapies related to wounded warrior injuries and rehabilitation.”
To learn more, see my recent interview with Dr. Jon Rowley, Founder and CEO of RoosterBio, or read the full press release from RoosterBio below.
RoosterBio Inc and the US Army Institute of Surgical Research (USAISR) sign a CRADA to accelerate development of Regenerative Medicine
Frederick, Maryland; July 27, 2016 — RoosterBio Inc, a leading stem cell technology company, announced today that they have entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Institute of Surgical Research (USAISR) at Fort Sam Houston, Texas. The 3-year CRADA, entitled “Evaluation of Cellular Therapies for Treatment of Trauma-Related Injuries: Standardization of MSC (Mesenchymal Stem/Stromal Cell) Methods, Identification, and Usage,” enables collaborative development of innovative stem cell-based therapies related to wounded warrior injuries and rehabilitation.
The Department of Veterans Affairs reported that it had treated more than 1 million service men and women at their hospitals since the end of the Iraq and Afghanistan wars, many of which suffered from severe burns, brain trauma, musculoskeletal ailments and limb loss. This number of patients seen by Veterans Affairs hospitals is expected to reach 1.5 million in the coming years, as more veterans seek treatment. The executed CRADA combines USAISR’s research experience in MSC function and related analytical testing with RoosterBio’s expertise in consistently manufacturing large volumes of MSC products for use in advanced Regenerative Medicine applications.
The resulting collaboration offers a unique opportunity to rapidly revolutionize cellular therapy practices and the current standard of patient care, thereby drastically improving both battlefield and civilian trauma treatment and outcomes.
This endeavor is critical, as the number of injured soldiers seeking care continues to increase.
The USAISR Blood Research Program, led by LTC (P) Andrew Cap, is charged with developing cellular therapy solutions to support both acute trauma care and Regenerative Medicine applications. This collaboration with RoosterBio is anticipated to advance stem cell availability, supporting future clinical trials designed to explore new therapies for combat casualty care.
RoosterBio is currently working with USAISR to thoroughly characterize highly functional and standardized MSC starting materials specifically utilized in advanced wound healing and immunomodulation applications. This understanding will further drive rational design of stem cell manufacturing processes, as they relate to therapeutic strategies based on the MSC in vivo role during homeostasis and tissue repair. Jon Rowley, PhD, CEO of RoosterBio, will serve as Co-Principal Investigator.
Rowley shares, “Stem cells are central to both civilian and military applications of Regenerative Medicine, and MSCs are the most widely used purified stem cell type in clinical medicine today. These unique cells, when used as medical tools, have the capacity to transform the therapeutic approach and improve the degree of recovery for soldiers both on and off the battlefield. Working with LTC (P) Cap and his team at USAISR will accelerate our understanding of scalable production platform impacts on the functional properties of MSCs. This collaboration ensures the maintenance of critical stem cell functions needed for robust clinical translation of “off-the-shelf” products, designed for trauma applications.”
For further information, please contact Margot Connor at margot(at)roosterbio(dot)com.
About RoosterBio, Inc.:
RoosterBio, Inc. is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable Regenerative Medicine industry, one customer at a time. RoosterBio’s products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers.
The Company has demonstrated that their cells can be used directly out of thaw – eliminating the expansion step from initiating an experiment. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio and adult stem cells, please visit http://www.roosterbio.com, follow on twitter (@RoosterBio), or read the blog “Democratizing Cell Technologies” (http://www.roosterbio.blogspot.com).
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Xconomy, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.